Regulus Therapeutics (RGLS) Tops Q3 EPS by 3c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.37), $0.03 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $1.2 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Prestige Consumer Healthcare closes LaCorium deal, prices $400M notes
• Morgan Stanley Downgrades Seven & i Holdings Co Ltd (3382:JP) (SVNDF) to Equalweight, Earnings US May Peak F2/27